magnifying glass
logo for Fujifilm Kyowa Kirin Biologics

Fujifilm Kyowa Kirin Biologics

Japan · 28 Employees

Get Full Access

Who is Fujifilm Kyowa Kirin Biologics

Fujifilm Kyowa Kirin Biologics was established by FUJIFILM Corporation (President: Kenji Sukeno; "Fujifilm") and Kyowa Kirin Co., Ltd. (President and CEO: Masashi Miyamoto, "Kyowa Kirin") on March 27, 2012 as a company for developing, manufacturing, and marketing biosimilars. Its pipeline includes Equidacent® and Hulio®, an adalimumab biosimilar (Product Code: FKB327), a drug to treat a range of inflammatory diseases. By merging the technologies in advanced production, quality control, and analysis which Fujifilm has developed over many years through its photographic film business, with the proprietary technologies and know-how which Kyowa Kirin has accumulated through its biopharmaceutical R&D and manufacturing, Fujifilm Kyowa Kirin Biologics creates revolutionary production processes and reduces costs for the production of biosimilars. Through this partnership, the company will develop and manufacture reliable, high quality, and cost-competitive biosimilar products, and will commercialize these products in a timely manner. With this strategy, Fujifilm Kyowa Kirin Biologics aims to hold a leading position in the expanding biosimilar market.Read More

Headquarters

Headquarters

Chiyoda-ku, Tokyo, Japan
Phone Number

Phone Number

+44 1896668173
Revenue

Revenue

$7M
Fujifilm Kyowa Kirin Biologics's Social Media
Popular Searches

Fujifilm Kyowa Kirin Biologics Co Ltd

Fujifilm Kyowa Kirin Biologics Co. Ltd

Fujifilm Kyowa Kirin Biologics

Fujifilm Kyowa Kirin Biologics Co., Ltd., Eu Branc...

SIC Code 87,873
NAICS Code 54,541

Fujifilm Kyowa Kirin Biologics Org Chart

PhonePhoneEmailEmail
Atsushi Matsumoto
Atsushi Matsumoto

President

PhonePhoneEmailEmail

PhonePhoneEmailEmail

PhonePhoneEmailEmail
Illustration of an envelope

Fujifilm Kyowa Kirin Biologics Tech Stack

AWS Web Hosting

By

Amazon.com

Google Tag Manager

By

Google

jQuery

By

jQuery

Gmail for business

By

Google
See more technologies

Fujifilm Kyowa Kirin Biologics News & Media

Biosimilars Market Analysis, Size, Share, Trends, Global Industry Overview, Demand, Growth and Forecast 2028 Coherus BioSciences, Dr. Reddy's Laboratories Limited, Fresenius Kabi AG, Fujifilm Kyowa Kirin Biologics Co Ltd., Innovent Biologics, LG Chem

London, UK -- (SBWIRE) -- 06/07/2022 -- Biosimilars Market Size 2022 Global Trend, Industry News, Top Key Players Update, Industry Demand, Business Growth, Business Statistics and Research Methodology by Forecast to 2028 Read the full press release at http://www.sbwire.com/press-releases/biosimilars-market-analysis-size-share-trends-global-industry-overview-demand-growth-and-forecast-2028-coherus-biosciences-dr-reddys-laboratories-limited-fresenius-kabi-ag-fujifilm-kyowa-kirin-biologics-co-ltd-i

Viatris Launches Hulio® (adalimumab biosimilar) in Canada

18, 2021 /PRNewswire/ -- Viatris Inc. announced today that Health Canada has approved Hulio®i, and product is now available in Canada.

Mylan and Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval of Hulio® (adalimumab-fkjp)

HERTFORDSHIRE, England and PITTSBURGH and TOKYO, July 9, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Hulio® (adalimumab-fkjp), a biosimilar to AbbVie's Humira®...
Subscribe to Fujifilm Kyowa Kirin Biologics News

Frequently Asked Questions regarding Fujifilm Kyowa Kirin Biologics

See more information about Fujifilm Kyowa Kirin Biologics
4.4/5 on G2 Crowd